@article{Todoriko_Сем’янів_2020, title={Peculiarities of pulmonary tuberculosis in a COVID-19 pandemic}, url={https://infusion-chemotherapy.com/index.php/journal/article/view/89}, DOI={10.32902/2663-0338-2020-3.1-65}, abstractNote={<p><strong>Objective.</strong> To evaluate the features of pulmonary tuberculosis (TB) in a pandemic of coronavirus disease (COVID-19).</p> <p><strong>Materials and methods.</strong> Leading foreign technical sources on the course of TB during the COVID-19 pandemic have been developed.</p> <p><strong>Results and discussion.</strong> Respiratory tract infections remain the leading cause of morbidity and mortality from infectious diseases worldwide. The list of World Health Organization (WHO) priority projects for research and development at the end of December 2019 included only three pathogens: coronavirus of the severe acute respiratory syndrome (SARS-CoV), coronavirus of the Middle East respiratory syndrome (MERS-CoV), mycobacterium TB. In January 2020, SARS-CoV-2, which is the cause of COVID-19, was added to the list of priorities. On March 11, 2020, the WHO announced a pandemic of a new dangerous disease – COVID-19. The pandemic has bypassed all other health problems and has become key worldwide and continues to spread, especially in countries with a high burden of TB, including Ukraine. Modern measures for social distancing and staying at home make it difficult to implement a program to provide quality TB care. This can have serious consequences for existing and undiagnosed TB patients worldwide, in particular in low- and middle-income countries where TB is endemic and health services are poorly equipped. It will be important to ensure access to uninterrupted quality care and care for everyone with TB.</p> <p><strong>Conclusions.</strong> On average, TB detection in Ukraine decreased by 27.4&nbsp;%, and the incidence of TB among children decreased by 34.5&nbsp;%. These are alarming figures, because we know very well that within 6 months the number of TB patients has not decreased, they have simply stopped being diagnosed. Launched cases began to be registered more and more often, and in the conditions of strict quarantine patients – active bacterial isolates pose a threat to contact persons, especially from risk groups according to COVID-19. All of the above is a clear example of the future problem we will deal with in the coming years.</p&gt;}, number={3.1}, journal={Infusion & Chemotherapy}, author={Todoriko, L.D. and Сем’янів, І.О.}, year={2020}, month={Oct.}, pages={78-78} }